A Bahraini man waits to get a dose of a coronavirus disease (COVID-19) vaccine, at Bahrain International Exhibition & Convention Centre (BIECC), in Manama. (Reuters)
Bahrain’s Ministry of Health has approved the emergency use of the COVID-19 medication Sotrovimab, according to a statement issued on Thursday.
“Sotrovimab-VIR-7831” develops “monoclonal antibodies” and will be used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalization, the health ministry said.
According to the ministry, safety and efficacy evidence demonstrates a reduction in the number of cases requiring hospitalization for more than 24 hours and a reduction in the number of fatalities by 85 percent, when administered at an early stage of treatment.
Earlier this month, Bahrain approved the emergency use for regn-cov2 medicine, Regeneron Pharmaceuticals Inc’s and Roche’s newly authorized COVID-19 antibody combination, as part of its coronavirus treatment protocol to treat existing cases with mild and moderate symptoms.
